Related Experiment Video
Updated: Jul 15, 2026

Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device
Published on: September 24, 2020
Potential use of fluorocarbons in lung surfactant therapy
Frédéric Gerber1, Marie Pierre Krafft, Thierry F Vandamme
1Systèmes Organisés Fluorés à Finalités Thérapeutiques, Institut Charles Sadron, Strasbourg, France.
Abstract:
Exogenous surfactant therapy based on animal lung extract preparations has been developed successfully for the treatment of neonatal respiratory distress syndrome. However, because of the inherent limitations of these natural preparations, the development of new synthetic surfactants is a major objective. We report here that a perfluorocarbon gas (perfluorooctyl bromide, gPFOB) inhibits the formation of the semi-crystalline domains that occur during compression of a Langmuir monolayer of dipalmitoyl phosphatidylcholine (DPPC), taken as a simplified model of lung surfactant. gPFOB also facilitates the re-spreading of the DPPC monolayer. These results suggest that PFOB, a fluorocarbon already investigated for oxygen delivery, may be useful in lung surfactant replacement compositions.
Related Concept Videos
Breathing
Cystic Fibrosis: Management
Sinus disease and chronic sinusitis...
Acute Respiratory Failure-V
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Supercritical Fluid Chromatography
SFC utilizes a supercritical fluid mobile phase,...
Surface Active Agents

